ADVERTISEMENT
Research & Development
Novartis president, development and chief medical officer talks about the pivotal role of the development India hub in progressing breakthrough drugs, how AI is delivering gains in the trials arena, driving focus in the R&D engine and the Swiss group’s approach in the obesity space.
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
Argenx has discontinued Vyvgart for the rare skin disease as other potential candidates linger in the very early stages of development.
With new Phase I/Ib results in kidney cancer, the HIF-2a inhibitor outshines Merck’s Welireg, but longtime Arcus partner Gilead decided not to exercise its option for casdatifan.
General chapters on pyrogens, histamine and depressor substances – involving tests on rabbits, guinea pigs and cats – are being removed from the Ph. Eur, marking another step in the European Pharmacopoeia Commission’s ongoing efforts to replace, reduce and refine the use of animals for monograph requirements.
US consumer survey commissioned by NOW Health suggests energy could dominate wellness priorities in 2025 while CRN’s most recent survey showed use of specific supplements such as magnesium, prebiotics and ashwagandha increased compared to previous years. Overall interest in vitamin, mineral and supplement products is higher in several other countries, according to Statista.
Gingko Bioworks has released a large language model designed to improve mRNA stability.
Beyond the cost savings of biosimilars, the true evolution in wet AMD treatment is happening by companies developing next-generation therapies that aim to reduce injection burden, introduce novel mechanisms, and potentially alter disease progression.
The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.
The US company has voluntarily halted enrolment in BEACON-IPF of bexotegrast on the recommendation of the trial’s independent data safety monitoring board, leaving analysts puzzled over the drug's prospects for the lung disease.